However, since IFN-γ signaling blunts TH2 cell development and pathogenesis in asthma,79–84 it is plausible that repeated rIFN-γ therapy may gradually show positive outcomes with respect to airway physiology as well. The gene discussed is IFNG; the disease is asthma.